Financings Of The Fortnight Follows OvaScience’s Unique Route To Going Public
This article was originally published in The Pink Sheet Daily
Plus news on recent financial activity by Stem Cells Inc., Sanofi, Avalon Ventures and Aerpio Therapeutics.
You may also be interested in...
The biotech voluntarily suspended a U.S. trial of its IVF-enhancing cell therapy after receiving word from FDA that it needs to follow a different regulatory path.
Avalon-backed RQx will team with Genentech to discover and develop antibiotics against a novel, undisclosed target. The deal essentially is an exit for hybrid VC firm Avalon, which already has exit deals this year with BioMarin and Genentech.
Plus news on recent financings by Radius Health, Cempra, Ironwood and Acetylon.